Management of Idiopathic Sudden Sensorineural Hearing Loss

Mosnier, Isabelle; Bouccara, D.; Sterkers, Olivier

doi:10.1159/000027910

Cited by 11 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are in accordance with the main prognostic studies, showing a correlation between the initial hearing threshold and the recovery rate [Byl, 1984;Fetterman et al, 1996;Mosnier et al, 1999;Chang et al, 2005;Ceylan et al, 2007]. We found no association between the audiogram shape and the final hearing threshold, whereas the audiogram type appeared as an important prognostic factor in several studies based on the recovery rate [Byl, 1984;Chang et al, 2005;Tran Ba Huy and Sauvaget, 2005;Ceylan et al, 2007].…”

Section: Audiometric Patterns and Predictive Factors Of Final Hearingsupporting

confidence: 91%

Cardiovascular and Thromboembolic Risk Factors in Idiopathic Sudden Sensorineural Hearing Loss: A Case-Control Study

Mosnier

Stépanian²,

Baron³

et al. 2010

Audiol Neurotol

135

126

View full text Add to dashboard Cite

Objective: The pathogenesis of idiopathic sudden sensorineural hearing loss (ISSHL) remains unknown, but vascular involvement is one of the main hypotheses. The main objective of this study was to investigate the association between ISSHL and cardiovascular and thromboembolic risk factors. Study Design: Multicentric case-control study. Methods: Ninety-six Caucasian patients with ISSHL and 179 sex- and age-matched controls were included. Patients were evaluated on the day of the inclusion and 1 week, 3 weeks and 3 months later. Clinical information concerning personal and familial cardiovascular and thromboembolic risk factors and concerning the ISSHL was collected. Blood samples were collected for genetic analysis of factor V Leiden and G20210A polymorphism in the factor II gene. The severity of the hearing loss was classified as mild (21–40 dB), moderate (41–70 dB), severe (71–90 dB) and profound or total (>90 dB). Hearing improvement was calculated as a relative improvement of hearing thresholds using the contralateral ear as baseline. Results: Systolic blood pressure was higher in patients (130 ± 1.7 mm Hg) than in controls (124 ± 1.1 mm Hg, p = 0.003). The personal/familial history of cardiovascular events was also more prevalent in patients (p = 0.023 and p = 0.014, respectively), whereas no difference was found in the prevalence of personal cardiovascular risk factors (hypertension, diabetes mellitus, hyperlipidemia, smoking habits). There was no correlation between the audiogram type, the hearing outcome and the presence of cardiovascular risk factors. No significant difference was observed in the personal/familial history or in the presence of thromboembolic risk factors. The prothrombin and factor V mutations were uncommon in both patients and controls. The final hearing threshold was only correlated with the severity of the initial hearing loss (p < 0.001), but not influenced by the presence of vertigo, audiogram type, time elapsed from onset of ISSHL to hospitalization or failure of a previous oral therapy. Hearing stabilization was obtained at 21 days in 92% of patients. Conclusion: These results support the theory of vascular involvement as the etiology of some cases of ISSHL. The sole predictive factor of poor final hearing is the severity of the initial hearing loss.

show abstract

Section: Audiometric Patterns and Predictive Factors Of Final Hearingsupporting

confidence: 91%

Cardiovascular and Thromboembolic Risk Factors in Idiopathic Sudden Sensorineural Hearing Loss: A Case-Control Study

Mosnier

Stépanian²,

Baron³

et al. 2010

Audiol Neurotol

135

126

View full text Add to dashboard Cite

show abstract

“…There are two hypothesized causes: viral infections and vascular events resulting in a local decrease in blood flow [80]. Steroids have some effectiveness in treating SSNHL, and the best indicators of treatment success are the severity of hearing loss and the time before treatment is started [80]. …”

Section: Inner Ear Drug Delivery Applicationsmentioning

confidence: 99%

Inner ear drug delivery for auditory applications

Swan

Mescher

Sewell

et al. 2008

Advanced Drug Delivery Reviews

173

146

View full text Add to dashboard Cite

Many inner ear disorders cannot be adequately treated by systemic drug delivery. A blood-cochlear barrier exists, similar physiologically to the blood-brain barrier, which limits the concentration and size of molecules able to leave the circulation and gain access to the cells of the inner ear. However, research in novel therapeutics and delivery systems has led to significant progress in the development of local methods of drug delivery to the inner ear. Intratympanic approaches, which deliver therapeutics to the middle ear, rely on permeation through tissue for access to the structures of the inner ear, whereas intracochlear methods are able to directly insert drugs into the inner ear. Innovative drug delivery systems to treat various inner ear ailments such as ototoxicity, sudden sensorineural hearing loss, autoimmune inner ear disease, and for preserving neurons and regenerating sensory cells are being explored.

show abstract

“…The jugular vein which takes the blood back from the brain area exits at the temporal bone lower level and courses through and indents a portion of the temporal bone [see figure 1]. In regard to what is commonly felt to be the ear, there is an outer ear, a middle ear and an inner ear [45]. Taking the outer ear first, we see the pinna or the ear cosmetically speaking, which resides on the lateral temporal bone.…”

Section: Anatomy Of the Earmentioning

confidence: 99%